Cellectar Biosciences, Inc.
Financial Services · Biotechnology
Listed: NASDAQ: CLRB
Facts
as of Nov 17, 2026Cellectar Biosciences is focused on the discovery and development of drugs for the treatment of cancer. The company is developing proprietary drugs independently and through research and development collaborations.
- Legal name
- Cellectar Biosciences, Inc.
- Headquarters
- Florham Park, United States
- Employees
- 201-500estimated range
- Listing
- NASDAQ: CLRB
- Register numbers
- NAME cellectar biosciences inc
- Official records
- SEC CIK 1279704
- Website
- cellectar.com
These are the key facts about Cellectar Biosciences, Inc. on Alion as of Nov 17, 2026. Cellectar Biosciences, Inc. is headquartered in Florham Park, United States. It has raised $50M in 3 funding rounds. The latest round is Venture - Series Unknown of $24.5M, announced in 2023.
Sources: company registers, GLEIF, Wikidata, the company's site, Alion job postingsReport a mistake
What the registers and the postings say about this employer.
Legal entity active
Cellectar Biosciences, Inc.
Not checked
Sanctions lists
OFAC SDN, EU consolidated
No match
Phishing reports
OpenPhish, Phishing.Database
None
Layoff notices
US WARN notices on file
None
Full employer checkScam signs in adverts, mail records, visa registers, domain history
Sources: company registers, the Alion truth index, OFAC and EU sanctions lists, US WARN notices
Footprint
Hiring in 1 city in 1 country.
1Cities
1Countries
| Site | Type | Open roles | Hires most for | Engineering |
|---|---|---|---|---|
| Florham Park United States | Headquarters | 0 |
Source: office addresses in postings and company registers
Financials
Funding rounds, investors and revenue on record.
$50MTotal raised
$4MPublic grants2 public grants
Venture - Series UnknownLatest round
5Rounds and grants
Money by yearUSD, rounds and grants
Largest rounds and grants
$24.5M
$20.5M
$5M
2022
$2M
2021
$2M
Sources: funding announcements, grant and company registers
Milestones
Nov 2026
Went public NASDAQ: CLRB
Sep 22, 2023
Board appointment Asher Chanan-Kahn, Director · SEC Form D
Sep 8, 2023
Raised a round Venture round $24.5M · SEC Form D
Sep 16, 2022
Won a grant $2M · CORDIS
Jan 8, 2021
Board appointment John Friend, Director · SEC Form D
Each milestone is dated by its source: registers, filings, the press
